由于大型跨国公司扩大研发和生产,中国的外国投资在2025年至2026年的高科技领域激增. Foreign investment in China surged in high-tech sectors in 2025–2026, driven by major multinationals expanding R&D and production.

根据新15年五项计划, 外资在中国正急剧转向先进制造业,生物药品和半导体等高科技领域. Foreign investment in China is shifting sharply toward high-tech sectors like advanced manufacturing, biopharmaceuticals, and semiconductors under the new 15th Five-Year Plan. 包括伊利莉,阿斯特拉泽内卡,瑞,拜耳和米其林在内的大型跨国公司正在扩大上海,北京和广州等城市的研发,生产和创新中心. 承诺总额达数十亿美元. Major multinationals including Eli Lilly, AstraZeneca, Pfizer, Bayer, and Michelin are expanding R&D, production, and innovation hubs in cities like Shanghai, Beijing, and Guangzhou, with commitments totaling billions. 中国生物制药行业在2025年取得了创纪录的130亿美元出境许可协议. China’s biopharma industry saw record $130 billion in outbound licensing deals in 2025. 官方数据显示,2025年新外资企业同比增长了19.1%,而2026年1月则增加了25.5%,高科技行业实际使用外国资本在当月上升175.1%. Official data shows a 19.1% year-on-year rise in new foreign-invested enterprises in 2025 and a 25.5% jump in January 2026, with high-tech sectors seeing a 175.1% surge in actual foreign capital use that month. 尽管全球投资下降和地缘政治挑战,但中国的投资格局正面临着向创新驱动高质量增长方向结构性转变. Despite global investment declines and geopolitical challenges, China’s investment landscape is undergoing a structural shift toward innovation-driven, high-quality growth.